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Abstract: Good medicine is based on good science, inquiry driven and open to new paradigms.
For a complex disease such as cancer, a complex treatment regime that is well structured and
multifactorial is indispensable. In the present day, Complementary and Alternative Medicine (CAM)
therapies are being used frequently for cancer, alongside modern biological therapies and allopathic
medicine, in what is called integrative oncology. In all conscience, the use of natural, less invasive
interventions whenever possible is ideal. However, a comprehensive understanding of not only the
etiopathology of individual cancers, but also the detailed genetic and epigenetic characteristics, the
cancer hallmarks, that clearly show the blueprint of the cancer phenotype is a requisite. Different
tumors have a common behavioral pattern, but their specific features at the genetic and epigenetic
levels vary to a great extent. Henceforth, with so many failed attempts to therapy, drug formulations
and combinations need a focused pre-assessment of the inherent features of individual cancers to
destroy the tumors holistically by targeting these features. This review therefore presents innocuous
therapeutic regimes by means of CAM and integrative medicine approaches that can specifically
target the hallmarks of cancer, using the case of cervical cancer.
Keywords: biological therapy; cervical cancer; human papillomavirus (HPV); cancer hallmarks;
integrative medicine; nutraceuticals; oncoproteins; tumor-associated antigens (TAAs)
1. Introduction
For eons, treating cancer using conventional chemo and radiation therapy has been in
practice regardless of the many side effects that these two therapies cause. Used separately
or combined as concurrent chemoradiation, patients have suffered lethal side effects;
and in other instances, the therapy is in fact the cause of morbidity and other lethal
outcomes [1,2]. To minimize the occurrence of detrimental side effects and poor treatment
outcomes, a team of health professionals including oncologists, physicians, surgeons,
nurses and other allied health professionals perform a careful assessment of individual
cases to develop the most logical therapeutic option. In the present day, this team of
professionals now includes Complementary and Alternative Medicine (CAM) specialists to
integrate allopathic medicine with CAM for cancer treatment. This is commonly referred
to as integrative medicine and has, in many studies, shown improved post-therapy quality
of life than when allopathic medicine is used alone [3].
Publications on the use of natural products for the treatment of disease can be back-
dated to as early as 1550 BC when the use of therapeutic plants was described in many
ancient publications of ancient Egypt, India and China [4]. The increased attention given
to CAM therapies now stems back from these ancient discoveries and, to date, there is a
promising future in the use of these therapies, especially alongside standard treatments. In
addition to CAM and as a part of alternatives to conventional chemo and radiation therapy,
modern cancer research has focused on the use of biological therapies to remove tumors
with the least risk of side effects. The application of these, requires a deep understanding
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of not only the etiopathology of cancer but also the genomic and epigenetic characteristics
of the cancer to clearly describe its inherent features. Beyond the intrinsic characteristics of
the cancer cells, other considerations at the tissue level including the tumor microenviron-
ment and immune environment are important factors in tumor survival and consequently
therapeutic outcome. Existing biological and physiological cancer therapies are being
considered for integration with CAM and allopathic medicine, with the aim of maximizing
tumor eradication while reducing side effects.
In this review, cancer of the uterine cervix (CaCx, cervical cancer) is used as model
for the development of such therapies. CaCx is the second most common gynecological
malignancy worldwide and recent data, according to the GLOBOCAN estimates, as of 2018
shows that CaCx is the fourth most frequently diagnosed cancer, and also the fourth leading
cause of cancer death in women worldwide [5]. CaCx arises from neoplastic transformation
of cells at the squamocolumnar junction after initial infection of the basal layer of the cervix
by the human papillomavirus (HPV). HPV is well established as the main causative agent
of CaCx, reported in nearly all of diagnosed cases [6]. The integration of HPV into the host’s
cell genome leads to disruption of the normal cell cycle and immortalization. Since the
first description of CaCx by Hippocrates, extensive studies have clarified the mechanisms
of growth and maintenance of CaCx, and today CaCx is one of the few cancers whose
etiopathology is exceptionally studied and understood. This knowledge has since provided
very useful technologies for the prevention, diagnosis and management of the disease.
This review thus presents the usability of CAM and biological therapies used alone
and integrated to achieve maximum anticancer effects while minimizing the risk of side
effects for conventional chemo and radiation therapies. A full account of the present
understanding of HPV and CaCx is given in order to examine the inherent features that
play important roles in CaCx and its subsequent response to therapy, which should be the
target when designing biological therapies and when considering the use of CAM therapies
by means of an integrative medicine approach. However, though this review focuses on
CaCx, the dogma and principles of therapies discussed here are inferable to other cancer
types by firstly studying the inherent features of each cancer, followed by the assessment
of available compounds that can target the respective inherent features. Some features are
common between a wide range of cancers, whereas others are cancer specific, hence the
need to thoroughly examine features of cancer when designing therapies. For the relevance
of this discussion, a brief introduction to the morphology of cancer is given, followed by a
detailed etiopathology of CaCx, to set foot on inherent features to be discussed and finally
the analysis of those inherent features which CAM and integrative medicine can target to
achieve the desired therapeutic outcome proceed.
2. The Hallmarks of Cancer
Unlike most diseases that affect the human organism, and can be distinguished
from the normal physiological lieu, cancer is a very dubious one that cannot easily be
distinguished and yet targeted using medication. In histological examination of tumor
tissues, the changes appear more evident but biologically when in vivo, the body’s own
cells including the immune system cannot easily identify the cells and pharmacological
agents are not any better in achieving the distinction, and this explains the many side
effects of cancer therapy. Because of this complexity, present therapies for cancer are being
designed to be more specific and directive to the specific characteristics of cancer, referred
to as ‘the hallmarks of cancer’. Shown in Figure 1 below are the hallmarks of cancer,
characteristics of cancer cells that determine their survival and maintenance in the body.
The annotations in the image above have been established based on the outcomes of
extensive research that have shown that genomic alteration in cancer occurs at multiple
points, progressively, from a single genetic abnormality to the acquisition of numerous
malformations that transform the normal cell to cancer cells [7,8]. Furthermore, tumor
cell maintenance has been explained by other colleagues including Otto Warburg, who in
1926 explained the metabolism of cancer cells using aerobic glycolysis [9], a phenomenon
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commonly referred to as “the Warburg effect”, where energy is acquired form aerobic
glycolysis through the increase in the rate of glucose uptake and preferential produc-
tion of lactate [10,11]. The microenvironment of tumor cells has also been extensively
studied [12,13], and shown to be acidic, in which cancer cells tend to thrive better. In CaCx,
the integration of the HPV genome into the host’s genetic material is another important
hallmark that has therapeutic implications [14]. Specific targeting of these characteristics,
therefore, is essential in order to ensure maximum cancer eradication with minimal, if any,
effect on normal cells. The following section therefore discusses cervical carcinogenesis to
pinpoint the characteristics that can be targeted by CAM and biological therapies.
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epithelial cells and the endocervix is lined with columnar epithelial cells forming a visible 
drift at the meeting point due to the difference in thickness. Because of this difference, 
there is a unique interface that is formed where the two epithelia meet, called the 
squamocolumnar junction [15]. 
Physiologically, before menarche, the squamocolumnar junction lies on or proximal 
to the external os where the acid-sensitive columnar cells are not exposed to the low pH 
of the vagina. However, during puberty and pregnancy, the cervix enlarges and bulges 
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3. Cervical Carcinogenesis
Understanding the features of cancer begins with comprehension of the anatomy
and hysiology of the tissue of origin. This is very important because the behavior of
m st cancers, especially in the early stages, is related to the physiology of thei tissue
of origin. Hence, in the discussi n of the inherent features of CaCx, the p ysiology of
the c rvix is crucial. The uteri e cervix is a cylinder-shaped neck of fibromuscular tissue
connecting the vagina and the ute us. The cervix comprise two parts—the part that
projects into the vagi a, called portio vaginalis, and a portion that lines the internal
part, called the supravaginal portion. Toward the uterus from the cervix, the mucosa
lining the cervical canal is known as t e e docervix, which separates from the ectocervix
at the external os. Though with a continuous surface, the endocervix and ectocervix
are microscopically different. The ectocervix is norm lly covered with non-keratinized
stratified squamous epithelial cells and the endocervix is lined with columnar epithelial
cells forming a visible drift at the meeting point due to the difference in thickness. Because
of this difference, there is a unique interface that is formed where the two epithelia meet,
called the squamocolumnar junction [15].
Physiologically, before menarche, the squamocolumnar junction lies on or proximal to
the external os where the acid-sensitive columnar cells are not exposed to the low pH of
the vagina. However, during puberty and pregnancy, the cervix enlarges and bulges out
into the vagina exposing the columnar cells of the endocervix to the acidic environment
of the vagina. This phenomenon, referred to as cervical ectopy or ectropion, results in a
physiological metaplastic change (i.e., transformation) from columnar to squamous cells.
However, the type of metaplasia that occurs at this part of the cervix is not a direct change
from columnar into squamous cells, as is the case with most cellular adaptation processes,
but rather a replacement of the cells due to proliferation of subcolumnar cuboidal reserve
cells, hence called reserve cell hyperplasia or indirect metaplasia. The area where this
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metaplastic change occurs is called the transformation zone and it is the point at which
cervical cells are very susceptible to neoplastic change.
With the physiological events that occur at the transformation zone and the fast cellu-
lar turnover of the stratified epithelium of the cervix, HPVs find a safe haven for settlement
and continuation of their life cycle. In most women, the activities in the transformation
zone result in the development of a mature epithelium composed of normal glycogen-
containing metaplastic squamous epithelial cells, very similar to the original squamous
cells. With the presence of HPV infections, or sometimes occasionally, it may result in
the formation of abnormal, dysplastic epithelium with atypical cells showing impaired
structures. These abnormal cells follow either of three outcomes—they may shortly prolif-
erate then spontaneously revert to normal cells, they may continue proliferating to form a
dysplastic epithelium or they may slowly progress to become malignant cells usually with
persistent HPV infection over a long period [15].
The advanced knowledge about the structure of the viral particle and full comprehen-
sion of the functions of its proteins has significantly contributed so much to the management
of CaCx and the development of novel therapeutic methods. All papillomaviruses are
small, non-enveloped viral particles containing a single molecule of double-stranded DNA
approximately 8000 base pairs in length. Three functional parts can be exclusively denoted
in the ORFs. These include the early (E) region, late (L) region, and a long control region
(LCR), which contains the non-coding part of the genome but has cis-acting elements
necessary for replication and transcription of the viral DNA. Viral proteins E1, E2, and
E4–E7 are transcribed from the E region and play important roles in viral replication. The L
region encodes L1 and L2 proteins that are necessary for assembly of the viral particles [16],
as shown in Figure 2 below.
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During the development of CaCx, integration events leading to the selective expression
of E6 and E7 genes occur. These events then influence the regulation of the cell cycle, mech-
anisms of apoptosis and cellular proliferation. The E6 and E7 oncoproteins bind to a wide
range of host regulatory proteins, specifically p53 tumor suppressor and retinoblastoma
proteins, respectively, leading to their degradation and functional inactivation. Further-
more, E7 oncoprotein induces entry of the S phase in cells that are not scheduled for cell
division. Direct association and degradation of members of the retinoblastoma (Rb) family
that are involved in the regulation of terminal differentiation achieve this. Eventually,
this genomic alteration leaves the infected cell unstable and inclined to acquisition of
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further mutations, which includes several missense, nonsense, silent, non-coding, splice
site, non-stop somatic mutations and a few frameshift and in-frame indels [17].
Before the onset of cancer, however, there is an array of noticeable precancerous lesions
that have been described as early stages of cancer. Referred to as Cervical Intraepithelial
Neoplasia (CIN), these changes indicate the premalignant phase of HPV infection that
may regress or progress to cancer. According to the degree of dyskaryosis (extent of
damage), CIN is divided into three stages denoted with Roman numerals as grade I, II and
III. CIN grade I indicates mild dysplasia and is also referred to as low-grade squamous
intraepithelial lesions (LSIL). CIN II and III are moderate and high dysplastic changes,
respectively and are known as high-grade squamous intraepithelial lesions (HSIL). CIN III
has dysplastic cells covering the entire thickness of the epithelial tissue and is therefore
called carcinoma in situ. At this stage, the atypical cells have the highest potential to
become invasive and can ultimately invade the basement membrane causing CaCx.
4. Innocuous Integrative Oncology for Cervical Cancer
The ultimate goal of therapy is to achieve physiological normalcy post-therapy, but
this is not always the case for cancer because of the toxicity of the available allopathic
medicine to date. Current conventional treatments approved for CaCx include surgery,
chemotherapy, and radiation and have numerous side effects. Because of the characteristics
of cancer shown in Figure 1 above, it is evidently not easy to develop a therapy that
completely destroys the tumor without affecting normal tissue. To date, the acceptability of
approved therapies other than surgery depends on their capacity to reduce cancer growth
at doses that have noticeable but with the least side effects. Although the decision for
therapy is made having considered many variables including the size and shape of the
tumor at diagnosis, the stage of the cancer, the woman’s age and general medical conditions,
the individual’s desire to have children later in life, there are still numerous side effects
during and after treatment. These have been substantially reviewed elsewhere [18–20] and
summarized in Table 1 below.
Table 1. Common side effects of conventional therapy to cervical cancer.








• Hair loss (alopecia)
• Nausea and vomiting
• Pain
• Sleep problems and insomnia
• Fertility loss
• Physical and psychological sexual
disorientation
• Pain at the incision site
• Blood loss
• Infection
• Damage to the bladder or intestines
4.1. Complementary and Alternative Medicine (CAM) Therapies
Complementary and Alternative Medicine (CAM) Therapy is simply defined as a
group of all medical and health care systems, practices and products that are not normally
considered to be conventional medicine. The two are technically the same thing, only
defined as ‘complementary’ when they are used together with conventional medicine and
‘alternative’ when they are used in place of conventional medicine [21]. This definition
denotes a very broad part of medicine that includes mind–body interventions, manipu-
lative and body-based procedures, energy therapies, biologically-based treatments, and
alternative medical systems. The common use of complementary therapies in oncology is
not necessary with the attempt to cure but rather as supportive therapies and hence mainly
used to alleviate symptoms of conventional therapy and also in palliative care. Shown in
Table 2 below are common CAM therapies used as part of cancer therapy.
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cially most nutraceuticals including vitamins, herbs and supplements [36] details of which
are given in proceeding sections below. However, these need very careful administration
when used alongside allopathic medicine, which is the case when treating cancer. When
used alongside chemo agents, certain compounds in these natural products can affect
how the drug works [37]. Additionally, cancer is a complex disease with many molecular
processes that are responsible for the tumor phenotype and different compounds can slow
down or speed up the cancer growth. Hence, a careful assessment is utterly important. In
all conscience, for complex diseases such as cancer, even allopathic therapies to date have
many limitations in eradicating the tumor. Likewise CAM therapies cannot be used alone
to treat cancer. Therefore, integrative medicine is the common practice in the modern day,
where CAM therapies are used alongside allopathic medicine to treat cancer. The correct
use of integrative medicine enables a holistic approach to therapy that ensures that the
body’s innate healing response works together with medical interventions to effect on not
only the disease but also the other aspect of the body, e.g., mind, spirit and overall health,
things that do have so much influence on the outcome of mainstream therapies [38].
4.2. Biological Therapies
In addition to the benefits of natural products and compounds, less invasive biological
interventions, are useful for treating cancer. Conventional chemotherapy, radiotherapy and
surgical therapy are commonly used for cancer, but this age has seen a great advancement
in studies performed on non-conventional medical treatments with many of those being
investigated in thousands of clinical trials at any given time. More research in vitro also
continuously presents the basis of novel approaches to therapy and elaborates on cancer
cell biology and their response to several therapeutic agents. To minimize the risk of side
effects induced by synthetic pharmaceutics and invasive therapies, biological therapies as
an alternative approach for treating cancer are the modern therapeutic options. Most of
these, though used frequently in many clinical trials, have not been approved as allopathic
(mainstream) therapies, hence they are included in the category of alternative medicine.
Biologically based therapy for cancer involves the use of living organisms, substances
derived from living organisms, or laboratory-produced versions of such substances to treat
the disease. Their application stops cancer by directly acting against cancers or indirectly
through stimulation of the body’s immune system to act against the cancer cells. Another
class of biological therapies also stops cancer growth by interfering with molecules that
play a maintenance role for tumor growth and progression [39,40].
Very few biological therapies have since been approved (see FDA-approved biological
therapies), and many others are still in clinical trials and in vitro. Overall, biological thera-
pies are a focus of modern cancer therapeutics. Examples of such therapies include but are
not limited to immune checkpoint modulators, drug immune conjugates, targeted drug
therapy, direct monoclonal antibodies (mAbs), oncolytic virus (OV) therapy, angiogenesis
inhibitors, cancer vaccines, chimeric antigen receptor (CAR) T cell therapy, gene therapy,
and cytokine therapy. Because biological therapies are recent discoveries with so much
work continuously being performed, there are certain limitations in their nomenclature.
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Thus, other oncologists propose the use of another parameter that describes the mode of
action of the therapy in terms of whether it involves a physiological process. Physiological
therapies therefore refer to those that work by means of a function of the human body.
Furthermore, other scientists will refer to biological therapies as immuno-oncology ther-
apies, and distinction is lacking between certain categories, resulting in the inclusion of
a particular type in more than one category in as far as classification in concerned. For
the purpose of this discussion, therefore, the common biological therapies are classified in
relevance to the discourse that follows in the discussion of inherent features of CaCx that
these therapies work on.
4.2.1. Immunotherapies
Molecular complementarity between cell surface antigens and their corresponding
immune elements, i.e., antibodies and cell recognition sites of lymphocytes, is the basis
of immune action. Because of this mode of action, cells of the body need a mechanism
of avoiding immune destruction even during an immune reaction. Apart from the Major
Histocompatibility Complexes (MHCs) that the immune cells recognize to avoid destroying
self-cells, an additional regulatory mechanism during an immune reaction to pathogens in
the body occurs to ensure self-tolerance [41]. Immune checkpoints are therefore conveyed
and represented by two different forms of signals including (1) co-stimulatory immune
checkpoints, those that stimulate the progression of immune reactions, and (2) co-inhibitory
immune checkpoints, those that inhibit the progression of immune reactions. Among the
co-inhibitory immune checkpoints are cytotoxic T-lymphocyte-associated antigen 4 (CTLA-
4), programmed cell death protein 1 (PD1), V-domain Ig suppressor of T cell activation
(VISTA), lymphocyte-activation gene (LAG)-3 [42,43].
The aforementioned checkpoints are designed to protect normal body cells from
immune damage during the immune reaction to the pathogens. Ideally, cancer cells should
be recognized by the immune system as foreign cells because of the many genetic and
epigenetic changes that occur during tumorigenesis, which provide antigens referred to
as tumor-associated antigens (TAAs). These TAAs initially are recognized by the immune
system and without a mechanism by the cancer cell to resist the immune action, tumors
would not survive in the body. Therefore, during the development of the tumor, the cancer
cells shrewdly dysregulate these immune checkpoints to escape immune attack even in
the presence of TAAs and immune surveillance [44]. The cancer cells also change their
antigen structures, downregulate important MHC molecules and/or secrete substance that
suppress the action of the immune system. Most cancer cells including cervical, upregulate
PD1 ligands which target the PD-1 on T cells, thereby suppressing the antitumor actions
of T cells (Figure 3). Because of this observed phenomenon, immunotherapies have over
the years been a commonly used biological therapy. The application of immunotherapies
is therefore based on the principle that blocking or modulating the ligands and receptors
that are necessary for the interaction of the cancer cell and immune cell for immune
tolerance does prevent the cancer cell from evading the immune reaction. The immune
checkpoints are initiated by ligand–receptor interactions that can be blocked using mAbs,
or recombinant technology.
4.2.2. Oncolytic Virus (OV) Therapy
Another interesting immune system activator is the OV therapy, which uses replication-
competent viruses to destroy cancer cells. The principle behind OV therapy is that, OVs
bypass normal cells to infect tumors resulting in continuous replication inside the cancer
cells thereby injuring the entire tumor [45]. The OVs are genetically modified to achieve
tumor selectivity plus oncolysis. Over the years, different types of OVs have been modi-
fied from viruses including the common Retroviruses, Paramyxoviruses, Adenoviruses
and Herpes simplex viruses (HSV). With a tiny minority of government-approved OVs
including the talimogene laherparepvec (T-VEC), adenovirus, and an HSV, most OVs are
still on the road to approval, currently in clinical trials and in vitro [46].
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Though very effective, as demonstrated by the efficacy of the approved OVs, data
regarding OV therapy suggest the need for further scientific expositions as there are a few
limitations thus far. Like most therapies, a very important observation with the application
of OVs is the need for a carefully performed optimization protocol to find the balance
between maximal antitumor immunity and minimal antiviral immunity. This observation
is a typical example of a hormetic-type response of living cells to stressful substance.
Hormesis is a phenomenon where processes in a cell would display a biphasic response
after exposure to increasing amounts of a substance or condition, and is characterized by a
low-dose response that is opposite in effect to that seen at high doses, i.e., stimulation at
low doses versus inhibition at a higher dose [47]. In the presence of such a response, the
hormetic zone would refer to the range where there is an favorable biological response to
low exposures with no effect at high doses. This means that the OVs injected in the body
should not exceed the dose of the hormetic zone and that requires enough information
about the tumor including tumor mass, site and features of its microenvironment.
4.2.3. Anticancer Vaccines
Apart from the well-known and highly recommended HPV vaccines as prophylactic
for CaCx, vaccination for treatment is another growing field in cancer management. The
HPV vaccines, Cervarix and Gardasil, are given to new born or adolescent girls to prevent
cervical carcinogenesis after exposure to HPV in their life time. For diagnosed cases, a ther-
apeutic vaccine can also be designed for curative purposes and are in their application also
categorized as immunotherapies. When using therapeutic vaccines, the idea is based on the
concept of using overexpressed tumor-associated carbohydrate antigens (TACAs), proteins
and enzymes that are antigenic in cancer cells [48]. A common example is the sipuleucel-T
vaccine for the prostatic acid phosphatase (PAP) in prostate cancer, formerly approved
by the American FDA [49,50]. In the case of virally induced cancer including CaCx, viral
proteins and oncoproteins can also be used as targets for therapeutic vaccines. However,
hormesis as described previous is also an issue with the use of anticancer vaccines.
4.2.4. Targeted Therapies
The search for agents that can be directed towards cancer cells to avoid normal tissue
toxicity led to the discovery of varying types of targeted therapies. Simplified, a targeted
therapy is a type of treatment that uses drugs or other substances to identify and attack
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specific cancer cells without harming normal cells [51]. Certain immunological agents
are also categorized as targeted therapies. A common targeted therapy that uses mAbs
produced from a single clone of B lymphocyte, also called monoclonal antibody therapy,
employs the principle of specific Ab binding to specific antigens and hence achieving
directed/targeted tumor destruction specific enough to reduce severe side effects [52].
Because of the unique antigen–Ab interactions, the Abs can only recognize and bind to the
cancer cell that has the corresponding antigen, leading to antitumor reactions by either
blocking cell growth, preventing metastasis or inducing immunological reactions that cause
cytotoxicity. These mAbs can be used alone due to their immunological nature, or can be
used as carrier molecules for antitumor drugs, toxins, or radioactive materials directly to
cancer cells [53].
Another important type of targeted therapies that can also activate the immune system
at the tumor site but also has more prominent primary cytotoxic effects in itself is Photody-
namic Therapy (PDT). Currently approved in many countries and by the American FDA,
for treatment of some solid tumors, PDT has emerged as a potential treatment modality for
CIN and CaCx and shows many advantages over most putative CaCx therapies [53,54].
Pharmacologically, PDT uses not one, but two principles of selectivity and specificity to
maximally target the tumor cells with no effect on distant organs and very minimal or
rather negligible effects on surrounding cells [55,56]. This phenomenon is so because PDT
uses a couple of individual substances that are dependent on each other to attain reactivity,
and these independent substance are administered separately. In the first step, a photosen-
sitizing compound (photosensitizer or PS) is administered intravenously, intramuscularly
or topically and given time to selectively localized in the tumor because of the tumors
affinity to the drug. Once the drug has localized in the tumor, the second step involves light
irradiation, usually using a laser, specifically directed at the tumor in a single beam. The
light then activates the internalized drug and in the presence of tissue oxygen, cytotoxic
oxygen species and radicals are formed, which destroy the tumor cells from within, and
also from external effects upon destruction of the vasculature and activation of the immune
system [54–56]. The way PDT is delivered gives it not just one but two levels of specificity,
where the PS is selectively localized in the tumor tissue, and light is only directed to the
cancer region as shown in Figure 4 below.




Figure 4. The double selectivity and specificity of Photodynamic Therapy (PDT). 
5. Cancer Hallmarks Targetable by Innocuous Integrative Oncology 
The aforementioned hallmarks of cancer in Section 2 are necessary for cancer 
maintenance and survival. Attacking these features using innocuous biological therapies 
and CAM not only maximizes therapeutic efficacy, but also minimizes the risk of side 
effects since these features are either not found on normal tissues, or are expressed 
differently. These features therefore provide many opportunities for designing therapies 
that have the highest potential in eradicating tumor cells. The section below reviews how 
these features can be targeted in CaCx. 
5.1. Targeting the Genomic Instability 
Although they mimic normal cells of the body phenotypically, cancer cells have 
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them from their normal cell counterparts. The integration of the HPV genome into the 
cells’ own genome initiates a cascade of genetic instabilities that result first in the 
impairment of the p53 gene and the members of RB gene with a consequent increase in 
acquisition of more gene alterations and somatic derangements. In all cancers including 
CaCx, these genetic abnormalities allow for evasion of cell cycle control pathways and the 
initiation of the accumulation of somatic mutations [57,58]. This mechanism is the 
common initiation step for most cancers and is a significant tool that has therapeutic 
implications. 
However, in the midst of numerous genetic derangements that lead to cancer, a more 
important tool is the determination of mutational significance in cancer (MuSiC), which 
is aimed at separating the significant genetic events which are the important drivers in the 
pathogenesis of the cancer from the other less significant mutations that accompany the 
process [59]. During cervical tumorigenesis, many specific gene alterations directly 
related to the initial integration of HPV viral genome lead to a number of significantly 
mutated genes (SMGs) that provide data that are useful for designing gene-targeted 
therapies and immunotherapies. Most commonly affected genes in CaCx include HLA-A, 
Transforming Growth Factor Receptor 2 (TGFBR2), SHK-Binding Protein 1 (SHKBP1), 
Erb-B2 Receptor Tyrosine Kinase 3 (ERBB3), Caspase 8 (CASP8). These have prominent 
opportunities for therapy, for example the ERBB3 (HER3), which can be targeted using 
mAbs [60].  
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5. Cancer Hallmarks Targetable by Innocuous Integrative Oncology
The aforementioned hallmarks of cancer in Section 2 are necessary for cancer main-
tenance and survival. Attacking these features using innocuous biological therapies and
CAM not only maximizes therapeutic efficacy, but also minimizes the risk of side effects
since these features are either not found on normal tissues, or are expressed differently.
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These features therefore provide many opportunities for designing therapies that have the
highest potential in eradicating tumor cells. The section below reviews how these features
can be targeted in CaCx.
5.1. Targeting the Genomic Instability
Although they mimic normal cells of the body phenotypically, cancer cells have
genotype alterations that are better suited to be pharmacological agents than the phenotypic
properties currently used as targets for most therapies including chemo and radiation.
These genomic alterations give the cancer cells inherent features for their proliferation and
maintenance and are unique features that can be used to distinguish them from their normal
cell counterparts. The integration of the HPV genome into the cells’ own genome initiates
a cascade of genetic instabilities that result first in the impairment of the p53 gene and the
members of RB gene with a consequent increase in acquisition of more gene alterations and
somatic derangements. In all cancers including CaCx, these genetic abnormalities allow for
evasion of cell cycle control pathways and the initiation of the accumulation of somatic
mutations [57,58]. This mechanism is the common initiation step for most cancers and is a
significant tool that has therapeutic implications.
However, in the midst of numerous genetic derangements that lead to cancer, a more
important tool is the determination of mutational significance in cancer (MuSiC), which is
aimed at separating the significant genetic events which are the important drivers in the
pathogenesis of the cancer from the other less significant mutations that accompany the
process [59]. During cervical tumorigenesis, many specific gene alterations directly related
to the initial integration of HPV viral genome lead to a number of significantly mutated
genes (SMGs) that provide data that are useful for designing gene-targeted therapies and
immunotherapies. Most commonly affected genes in CaCx include HLA-A, Transforming
Growth Factor Receptor 2 (TGFBR2), SHK-Binding Protein 1 (SHKBP1), Erb-B2 Receptor
Tyrosine Kinase 3 (ERBB3), Caspase 8 (CASP8). These have prominent opportunities for
therapy, for example the ERBB3 (HER3), which can be targeted using mAbs [60].
Genome editing and gene therapies have shifted the therapeutic perspective by focus-
ing on treating disease at the genetic level with the use of nucleic acids. Gene therapies have
previously been discussed for the treatment of a wide range of different cancers [61–63].
However, many issues regarding their applications, pharmacology and ethical implications
have been debated for decades [64]. The idea of gene therapies is to use a method that
directly affects the function of a gene in order to archive a therapeutic target. Different
ways of approaching gene therapy have been described especially those that use a viral
vector [65], or nanoparticles [66] to effect cancer causing genes, e.g., p53, or to effect on
immune T cells that boosts immune reaction against cancer also called immunogenic ther-
apy. The constitutive role of HPV and its direct association with p53 and members of the
RB gene suggests the use of gene therapies [67]. Because of the restricted access to genetic
material in the body and the fact that most cancers are noted during the progression and
advanced stages, targeting the genetic material can be somewhat problematic unless in
cases where screening results in the confirmation of mutations at the initiation stage before
acquisition of alterations in SMGs. However, these mutations lead to the impairment of
molecular activities of the cell, the stage at which other therapeutic regimes can have much
effect, as describe in the following section.
5.2. Targeting Cell Signaling
Genetic alterations are very closely correlated with the alteration in their correspond-
ing molecular pathways. Hence, another important hallmark of cancer is the alteration of
cell signaling that enables the cancer cells to grow and create a sustainable environment
for themselves. At the molecular level, numerous therapeutic regimes can be developed
from biological therapies and CAM therapies, including nutraceuticals, nanoparticles (Ns),
and synthetic drugs. Although most nutraceuticals are evidenced for prevention and
management of cancer, their mode of action can also be utilized for treatment purposes as
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part of an integrative treatment regime. Naturally occurring nutraceuticals are easy to use
in certain instances—there is a need to incorporate or add nutraceuticals to food and this
has a significant impact on the physicochemical and sensory characteristics and structures
of the original food, a variable that needs proper assessment [24].
Cell signaling comprises a larger aspect of molecular mechanisms in the pathology
of cancer. Pathological events leading to tumorigeneses and tumor maintenance in most
cancers including CaCx involve the activation of Wnt/b-catenin, phosphatidylinositol-3
kinase (PI3K)/AKT, epidermal grow factor receptor (EGFR)/vascular endothelial growth
factor receptor (VEGFR), Ras/Raf/MEK/ERK, and the deactivation of cellular apoptotic
pathways. Although varying phenotypes of CaCx exist in different individuals, one or
more of the alterations in these pathways are found in the majority of cases, carried on
throughout the course of the disease, and provide an opportunity for the implementation
of CAM and design of biological therapies that target cell signaling.
5.2.1. Wnt Signaling Pathway
The Wnt signaling pathway plays a major role in the tumorigenic transformation of
HPV-infected cervical cells [65]. Activation of the Wnt signaling pathway leads to a series
of events that culminate to the accumulation of b-catenin in the cytoplasm, which promotes
its entrancement to the nucleus, finally activating the transcription of c-myc and cyclin D.
Although it is not feasible to target the Wnt/b-catenin pathway using a single forward
approach due to its complexity and the varying associated conduits within the pathway,
numerous compounds with significant effects on the pathway are available. Naturally
occurring polyphenols attenuate Wnt/b-catenin signaling via the induction of cellular
degradation of the b-catenin alongside a reduction in the nuclear accumulation of b-catenin.
The advantage of polyphenols is that they are abundant in nature, are found in a variety
of foods and can be extracted and used with less alteration. These compounds have both
defensive and therapeutic properties against most tumors. In CaCx, polyphenols have been
qualified for the sensitization of cancer cells to chemo and radiation [23]. Polyphenols are
categorized using five separate subgroups namely phenolic acids, curcuminoids flavonoids,
stilbenes, and lignans. Specific mAbs and peptides directed against different parts of the
Wnt/b-catenin pathway can be used [66]. For the purpose of maximally effecting on this
pathway therefore, an integrative approach using nutraceutical containing polyphenols
and mAb therapy can potentially produce better outcomes. To date, there are no reported
cases of a possible antagonistic mechanism between natural polyphenols and mAbs.
5.2.2. EGFR/VEGF Pathway
An important member of the tyrosine kinase receptor family, EGFR with its family
members Her/Erb, and ligands, are important regulators of carcinogenesis in many can-
cers including cervical. In addition to its varying downstream pathways, an important
downstream activity of EGFR is induction of the synthesis of VEGF upon stimulation
by EGF-activated signals, forming the EGFR/VEGF pathway. VEGF in turn, is an an-
giogenic factor, a dimeric glycoprotein that plays fundamental roles in the neogenesis of
vascular (and lymphatic) channels, both in physiological developmental processes and
pathological conditions such as cancer [68]. Because of its role in neoangiogenesis, this
pathway is vital for tumor maintenance and metastasis. Opportunely, there are numerous
EGFR/VEGF blockers that effectively target components of this pathway in use, in clinical
trials and in vitro. Bevacizumab is an FDA-approved CaCx targeted therapeutic agent for
the treatment of advanced/metastic CaCx, and recurrent disease [69,70]. This drug is a
recombinant humanized mAb, that immunologically targets VEGF-A in the EGFR/VEGF
pathway. Bevacizumab has been used for CaCx treatment in many clinical trials that led
to its approval, and continues to be used, with good patient prognosis despite its high
toxicity levels in some cases according to expert opinion. A tyrosine kinase inhibitor (TKI),
pazopanib also directly affects VEGF and is currently used for renal cell carcinoma and
other soft-tissue tumors though not currently approved for CaCx [71,72].
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Many other anti-EGFR mAbs and TKIs that target EGF and EGFR are available and
widely used for treating other cancers. Lapatinib, a potent TKI commonly used in the
treatment of HER2-positive breast cancer is a synthetic drug that targets both EGFR and
another member is the EGFR family ErbB2 (HER2). Though not widely used for CaCx,
clinical trials using lapatinib show potential use of this drug for the treatment of CaCx [72].
Other TIKs at varying stages of investigation include imatinib, Erlotinib, Matuzumab
and Gefitinib. Nimotuzumab is a mAb that shows very significant anti-EGFR activity
and has been studied in many CaCx clinical trials, with promising results in limiting the
progression of cancer [73]. A similar drug in action, Cetuximab, a chimeric mAb that blocks
this pathway by binding to the receptor causing it dimerization and downregulation, also
has promising anticancer effects [74].
5.2.3. PI3K/Akt Signaling Pathway
The PI3K/Akt signaling pathway is a very important element for the enhancement
of cancer cell proliferation and their survival in many solid tumors including CaCx. The
PI3K/Akt signaling pathway exerts its effects by downregulating the role of the Ras
signaling in the cell cycle, and modification of receptor signal transduction via its kinase
activity. This pathway is also one of the many downstream EGFR-associated pathways
described above. Blocking the pathway using PI3K inhibitors is a considerable method for
weakening early stage CaCx. Many compounds that directly interfere with the catalytic
subunit of PI3K by competing with ATP binding are available to avoid propagation of
CaCx. A naturally occurring metabolite of Penicillium funiculosum called Wortmannin (Wm),
which, apart from its direct effect on PI3K pathway, possesses features of chemosensitization
and radiosensitization is available for CaCx [75].
Another compound with similar properties, a derivative from flavonoid quercetin,
2-(4-morpholinyl)-8-phenyl-chromone (LY294002) also targets PI3K [76]. However, unlike
Wm, LY294002 possesses a very short life span with a higher off-target activity and high
toxicity, which restricts its clinical application. Several naturally occurring compounds have
anti-PI3K/Akt activity. Common ones include, genistein found in Soy foods, oridonin from
Rabdosia rubescens, triptolide from Tripterygium wilfordii, quercetin and rapamycin produced
from Streptomyces hygroscopicus, which targets and inhibits a downstream component of
the PI3K/Akt pathway known as the mammalian target of rapamycin (mTOR) [77,78].
5.2.4. Ras/Raf/MEK/ERK Signaling Pathway
Another important downstream EGFR-associated pathway is the Ras/Raf/MEK/ERK
signaling pathway, which plays vital roles in normal cell physiology. However, similar
to most of these signaling pathways, the Ras/Raf/MEK/ERK signaling pathway can be
activated in most cancers including CaCx [79]. EGF also plays an important role in the
activation of this pathway, leading to tumorigenesis and tumor maintenance. Briefly,
EGF-associated complexes involving RAF lead to the induction of MEK1 and MEK2,
which in turn phosphorylate and activate ERK1 and ERK2. Eventually, ERK1/2 acts on
a vast number of cell regulator substrates in both the nucleus and cytoplasm, including
cell cycle kinases, transcription factors and gene expression. In addition, Raf family
members are upstream activators of the ERK, which, when activated, induce the signaling
of ERK1/2 [80]. With so many intermediate signal regulators in Ras/Raf/MEK/ERK
signaling comes numerous inhibitor molecules that can be directed at different stages of this
pathway. Highly specific MEK1/2 inhibitors are under review including ERK1/2 antisense
oligonucleotides, PD98059 and U0126 [81]. The first inhibits ERK1/2 protein expression
and reduces its concentration in the cell and the other two inhibitors suppress ERK1/2
phosphorylation without changing the concentration of ERK1/2 in the cell. Because Raf is
an important upstream regulator, drugs that inhibit Raf, e.g., BAY43-9006 and Sorafenib, are
being considered for treating CaCx. Importantly, since the EGF is an important regulator
for this pathway, drugs that inhibit EGFR are similarly useful in preventing activation of the
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Raf/MEK/ERK pathway, which includes the possible incorporation of the nutraceuticals
previously described.
In principle, most of these pathways are related in one way or the other, with the
activation of one pathway imitating the regulation of another. Because of this phenomenon,
targeting one pathway, especially those upstream, results in the impairment of several
other pathways and, in all practical senses, the combination of drugs that inhibit different
pathways and different phases of their signaling has potential for resolute attenuation of
cancer propagation. However, care should be taken in the dosing and delivery of such
drugs and compounds due to the presence of similar pathways in normal cells that are
essential for continuation of life. In addition to that, the pharmacological interaction
between the different compounds when administered together should be evaluated.
5.3. Targeting Immune Evasion
Cancer cells have cellular regulation mechanisms for their maintenance and survival
in the body. These mechanisms including surface antigen expression (i.e., the TAAs),
extracellular vesicles that are secreted to mediate cell-to-cell communication and other
neoantigens [44]. At present, mAbs against CTLA4 are used for treatment of certain cancers
in most countries and blockers of PD1 are very close to being approved because of the many
clinical trials that have shown promising results. As shown previously, PD-L1 molecules on
the cancer cells stop the T cell from killing the cancer cell by attaching to the PD-1, a protein
on the surface of T cells [82]. With immune checkpoint inhibitors, ligands to prevent the
action on PD-L1 are used to activate T cells by blocking the PD-1 on the surface of the
T cells. A novel PD-1 checkpoint blocker used for most cancers including CaCx, called
Pembrolizumab, has shown promising results for treatment of recurrent tumors [83,84].
While nutraceuticals and mAbs inhibit angiogenesis at the molecular level, PDT can cause
damage to intact blood vessels via its cytotoxicity. Targeted therapies including PDT and
mAb therapy have also been useful in effecting cytotoxicity and tissue damage.
Although there are currently no licensed therapeutic HPV vaccines for cervical cancer,
studies have validated that vaccines have both prophylactic and therapeutic effects on
cervical cancer. Che et al. 2020 [85] studied the HPV16 E7 43-77 peptide and the adjuvant
unmethylated cytos 7ine-phosphate-guanosine oligodeoxynucleotide and demonstrated
that this vaccine had substantial effects on systemic immune responses and the tumor
microenvironment (TME) in a mouse model of cervical cancer. Their results indicated
a significant increase in interferon (IFN)-γ-producing CD4 and CD8 T cells and tumor-
infiltrating CD4 and CD8 T cells. Additionally, there was a marked decrease in splenic
myeloid-derived suppressor cells (MDSCs), regulatory T cells (Tregs), and M2-polarized
tumor-associated macrophages.
5.4. Targeting Angiogenesis
In some studies, mAbs, as described previously, can be used in a combination of two
or more mAbs to achieve a synergistic antiangiogenesis approach, which has shown better
outcomes [86,87]. In most cases, angiogenesis inhibitors have also been used alongside
conventional chemo and radiation therapies. In addition to these combinations, inhibition
synergism can also be achieved by the integration of a mAb and certain nutraceuticals. Such
compounds include but are not limited to the polyphenols previously described, curcumin
and epigallocatechin-3-gallate from green tea [88]. The integrative medicine approach using
angiogenesis inhibitors and nutraceuticals has previously been examined [89]. Although
there is limited understanding of the pharmacological interactions between these two
regimes, their combination for a possible synergistic action is pertinent.
Bevacizumab, previously described above, is the most common mAb therapy and
approved in most countries. In addition to Bevacizumab, other mAbs can be used to
target surface and intracellular proteins of the cancer and cause cytostatic or cytocidal
effects within the cell. A personalized neoantigen vaccine can also be applied. The added
advantage of the use of neoantigens is that they are new-fangled antigens produced mainly
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due to the infection, i.e., neo for new, and hence are only found on growing cancer cells [90].
This technique has the most potential for the least side effects, if any, since the vaccine can
only induce an immune response specifically targeting the mutated cancer cells without
cross effects on normal cells unless there is a secondary impact.
5.5. Targeting Oncoproteins
The role of HPV in cervical carcinogenesis makes the HPV oncoproteins good candi-
dates for therapeutic targeting. Although there is a minority of HPV-negative CaCx, up to
98% of CaCxs are HPV positive and the important function that these proteins play in the
development and maintenance of CaCx provides an opportunity through which therapies
can be designed. Because of the important role that HPV oncoproteins play, hr-HPV E6 and
E7 oncoproteins make attractive therapeutic targets [91,92]. The E6 and E7 oncoproteins
have been studied substantially and have been shown to localize inside the cell in high
concentrations, the site and concentration of which depends on many factors including the
stage of cell cycle and cell confluence in vitro. The presence of the E6 and E7 oncoproteins
in the nucleus, perinuclear region, cytoplasm and cell membrane, provides an opportunity
for targeting using mAbs, therapeutic vaccines and nutraceutical described previous [93].
Although there are no approved oncoprotein-targeting drugs to date, many studies
both in vitro and in vivo have indicated the potential of these drugs. Additionally, anti-
cancer vaccines against HPV oncoprotiens and p53 are being explored. However, Targeting
HPV oncoproteins is limited by the stage of cancer. Although the proteins are expressed in
cancerous cells during the course of disease, cancers acquire numerous other features that
are necessary for cancer propagation. That is to say, HPV is necessary for carcinogenesis,
but after the initial integration of the HPV genome that initiates transformation, numerous
other processes that result in genetic instability and the acquisition of other mutations
occur, resulting in genetically mutated phenotypes that become cancer cell independent
of the oncoprotein’s transforming effect for tumor maintenance. This is the reason why
the approach is more rational for CIN and early stage disease. However, the presence of
these proteins still provides an opportunity for targeted drug delivery of chemotherapeutic
agents and other anticancer drugs.
5.6. Targeting the Tumor Microenvironment
In addition to these, the tumor microenvironment contains elements including the
extracellular matrix, blood vasculature, immune cells and fibroblasts that play important
roles in the survival of the cancer cells. All these have therapeutic implications and
many biological therapies at varying stages of investigations have been designed. A
minority of those have since been approved (see FDA-approved biological therapies), and
many others are still in clinical trials and in vitro. tumor-associated macrophages, tumor-
associated blood vessels (TABVs), tumor-associated stromal cells (TASCs), and the acidic
surrounding in the tumor extracellular matrices are very important regulators of the tumor
microenvironment. The tumor microenvironment is an important hallmark of cancers,
hence a prefect target for safer therapies. In the tumor microenvironment, macrophages
play a very important role in carcinogenesis [94].
Another important feature in the tumor microenvironment is the presence of CD4+ T
regulatory cells (Tregs). A small number of Tregs circulate in the body naturally to function
as mediators of immune suppression to prevent autoimmune diseases. However, in cancer,
Tregs are recruited by tumor cells into the tumor microenvironment in order to inhibit anti-
tumor immunity [95]. Visser et al. [96] examined the frequencies, phenotype and activity
of (Tregs) in patients with cervical neoplasia and showed that both CIN and cervical cancer
patients had increased Tregs in the peripheral blood. In the tumor microenvironment, these
cells interfere with the action of the immune system by suppressing antigen-presenting
cells (APCs) through depletion of immune-stimulating cytokines followed by the expres-
sion of CTLA-4, which inhibits the APCs [97]. Additionally, they also limit the efficiency
of cancer immunotherapy. Using anti-CTLA-4 antibodies including ipilimumab (FDA
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approved for treatment of advanced melanoma) effectively reduces the action and number
of Tregs in the blood, with subsequent activation of cytotoxic T cells [98]. Although there
are no approved anti-CTLA-4-Treg inhibitors for CaCx to date, the presence of Tregs in
HPV-induced cancers including CaCx, suggests the use of monoclonal antibodies to act as
check point inhibitors in CaCx, but this remains to be an area of research [99,100]. Ji et al
investigated the combination of radiotherapy and suppression of Tregs in rectal cancer
and observed that this dual approach enhanced the efficacy of therapy with inhibition of
metastasis [101].
5.7. Therapeutic Strategies for Cervical Cancer to Date
At present, numerous therapeutic strategies for cervical cancer are available in clinical
trials, in vitro studies and in clinical practice. Current approved treatments for cervical
cancer include chemotherapy, radiation, surgery, immunotherapy and targeted therapy.
Conization is the removal of a cone-shaped piece of tissue from the cervix and cervical
canal and is the most widely used treatment for CINs, carcinoma in situ and stage I tumors
in most countries. The tissue can be removed using a scalpel (cold-knife conization); using
an electrical current passed through a thin wire loop as a knife called loop electrosurgical
excision procedure (LEEP); or using a laser beam to cut the tissue. Radical hysterectomy
or, most times due to technicalities, simple hysterectomy are often recommended as a
cure for locally advanced cervical cancer. Other surgical procedures in use include pelvic
exenteration (removal of all organs of the pelvis), lymphadenectomy (surgical removal of
the lymph nodes), and radical trachelectomy (the removal of the cervix and its surrounding
tissue, leaving the body of the uterus). Women with early stage disease who wish to
maintain fertility opt for radical trachelectomy with lymphadenectomy.
Chemotherapeutic drugs are mainly used as neoadjuvant or adjuvant therapies for
cervical cancer. Drugs used in many countries include 5-fluorouracil, paclitaxel, cy-
clophosphamide, cisplatin, carboplatin, and ifosfamide. In advanced localized cases,
concurrent/concomitant chemoradiation therapy (CCRT) is used as treatment or for pallia-
tive care. Because of the many side effects of external radiation on nearby organs such as the
bowel and bladder, internal radiotherapy (brachytherapy) is preferable. After metastasis,
Bevacizumab is used as a targeted therapy for prevention of angiogenesis by binding to
vascular endothelial growth factor (VEGF). Bevacizumab is also the treatment of option for
recurrent cancer. Thus, the only approved innocuous therapies widely accepted for CaCx
mAbs for targeted therapy, and some PD-L1 immune checkpoint inhibitors [102,103].
6. Conclusions
In conclusion, here we described and evaluated the use of CAM therapies, non-
invasive biological therapies and their combinations in the form of integrative medicine
for treating CaCx. With most, if not all, types of cancer, this approach can be considered in
order to maximize the benefits of therapies singularly or combined. However, there is still
a longer route to the acceptability and use of the varying types of therapies due to ethical
reasons and the need for clinical trials before their widespread acceptance and approval.
Cellular changes that occur to the cancer cell at the genome (i.e., DNA), molecular, and
morphological levels distinguish CaCx cells from their normal surrounding tissue and also
from other cancer cells for all practical applications. While allopathic medicine focuses on
the tumor with a specific mode of action, integrative oncology regimes can be designed
to focus on a wide range of targets in the cancer tissue. Additionally, we have analyzed
the inherent features of cervical cancer that can be used as targets for many nutraceuticals,
biological therapies and other CAM therapies. This case of cervical cancer can be applied
to the broad spectrum of cancers, having examined their inherent features at the genetic,
molecular, cellular, tissue and organism levels.
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